Aspartic acid

Generic Name: Aspartic acid

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinisol 15, Olimel, Periolimel, Plenamine, Premasol, Primene, Prosol, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₄H_₇NO_₄

CAS Number: 56-84-8

Unique Ingredient Identifier: 30KYC7MIAI

Background: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Indication: There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

Associated Therapies: Amino acid supplementation

Clinical Trials

The Effect of Vitamin D Supplementation on Psoriasis Severity

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Psoriasis

Interventions: Drug: 25-Hydroxyvitamin D
Drug: Placebo oral capsule

First Posted Date: 2017-11-07

Last Posted Date: 2020-10-08

Lead Sponsor: University Hospital of North Norway

Target Recruit Count: 115

Registration Number: NCT03334136

Locations: 🇳🇴
University Hospital of North Norway, Tromsø, Norway

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Regimen A
Drug: Regimen B
Drug: Regimen C
Drug: Regimen D

First Posted Date: 2017-10-17

Last Posted Date: 2020-06-11

Lead Sponsor: Pearl Therapeutics, Inc.

Target Recruit Count: 56

Registration Number: NCT03311373

Locations: 🇺🇸
Pearl Investigative Site, Baltimore, Maryland, United States

Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women

Phase 2

Completed

Conditions: Homocystinaemia
Vitamin D Deficiency

Interventions: Drug: Vit D
Other: Placebo

First Posted Date: 2017-10-16

Last Posted Date: 2017-10-16

Lead Sponsor: Al-Balqa Applied University

Target Recruit Count: 100

Registration Number: NCT03310307

Locations: 🇯🇴
King Abdullah University Hospital, Irbid, Jordan

Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? The D-Vex Pilot Study

Phase 4

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Stoss vitamin D
Drug: Daily vitamin D
Drug: Stoss placebo
Drug: Daily placebo

First Posted Date: 2017-08-22

Last Posted Date: 2025-03-14

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 13

Registration Number: NCT03257215

Locations: 🇦🇺
Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Phase 2

Completed

Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Interventions: Drug: JNJ-64179375 0.3 mg/kg
Drug: JNJ-64179375 0.6 mg/kg
Drug: JNJ-64179375 1.2 mg/kg
Drug: JNJ-64179375 (Dose to be Determined)
Drug: JNJ-64179375 A mg/kg
Drug: JNJ-64179375 B mg/kg
Drug: JNJ-64179375 C mg/kg
Drug: JNJ-64179375 D mg/kg
Drug: Placebo JNJ-64179375
Drug: Apixaban placebo
Drug: Apixaban 2.5 mg

First Posted Date: 2017-08-16

Last Posted Date: 2019-11-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 308

Registration Number: NCT03251482

Locations: 🇺🇦
Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, Ukraine
🇺🇸
Denver Metro Orthopedics, PC, Englewood, Colorado, United States
🇧🇪
ZNA Jan Palfijn, Merksem, Belgium

and more 100 locations

Efficacy of Topical Calcipotriol-assisted AFL-PDT in Actinic Keratosis

Phase 1

Completed

Conditions: Actinic Dermatosis

Interventions: Drug: Topical Vitamin D (Calcipotriol) application
Drug: Placebo cream application
Drug: lidocaine/prilocaine (5%) application
Drug: MAL application
Other: Measurements of the fluorescence intensity
Device: irradiation with red light-emitting diode lamp

First Posted Date: 2016-11-29

Last Posted Date: 2016-11-29

Lead Sponsor: Dong-A University

Target Recruit Count: 48

Registration Number: NCT02976727

Locations: 🇰🇷
Dong-A University, Busan, Seo-gu, Korea, Republic of, 602-715, Korea, Republic of

New Formulation and Food Effect Study of BIIB074

Phase 1

Completed

Conditions: Trigeminal Neuralgia (TN)
Other Neuropathic Pain

Interventions: Drug: BIIB074 Treatment C
Drug: BIIB074 Treatment A
Drug: BIIB074 Treatment B
Drug: BIIB074 Treatment D

First Posted Date: 2016-11-01

Last Posted Date: 2017-02-27

Lead Sponsor: Biogen

Target Recruit Count: 28

Registration Number: NCT02951221

Locations: 🇺🇸
Research Site, Daytona Beach, Florida, United States

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

Phase 3

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: burosumab
Drug: Oral Phosphate Supplement
Drug: active vitamin D

First Posted Date: 2016-09-27

Last Posted Date: 2024-08-29

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 61

Registration Number: NCT02915705

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 13 locations

Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Formulation A (ALS-008176)
Drug: Formulation G1 (ALS-008176)
Drug: Formulation B (ALS-008176)
Drug: Formulation G2 (ALS-008176)
Drug: Formulation C (ALS-008176)
Drug: Formulation G3 (ALS-008176)
Drug: Formulation D (ALS-008176)
Drug: Formulation H1 (ALS-008176)
Drug: Formulation E (ALS-008176)
Drug: Formulation H2 (ALS-008176)
Drug: Formulation F (ALS-008176)
Drug: Formulation H3 (ALS-008176)

First Posted Date: 2016-06-27

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT02813460

Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold

Phase 3

Conditions: Cold

Interventions: Drug: Resfenol
Drug: Coristina d

First Posted Date: 2016-04-12

Last Posted Date: 2016-04-12

Lead Sponsor: Brainfarma Industria Química e Farmacêutica S/A

Target Recruit Count: 366

Registration Number: NCT02735070

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy